{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:05Z","timestamp":1793295845546,"version":"4.5.0"},"reference-count":35,"publisher":"Scientific Scholar","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for &gt;five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown <jats:italic toggle=\"yes\">in vitro<\/jats:italic> activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir\/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_957_20","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T17:43:51Z","timestamp":1601574231000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":85,"title":["Clinical management of COVID-19"],"prefix":"10.25259","volume":"151","author":[{"given":"George M.","family":"Varghese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Manesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Karthik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.C.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R2-4-20241212","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - An update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res"},{"key":"R6-4-20241212","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-4-20241212","doi-asserted-by":"crossref","first-page":"20","DOI":"10.18332\/tid\/119324","article-title":"COVID-19 and smoking: A systematic review of the evidence","volume":"18","author":"Vardavas","year":"2020","journal-title":"Tob Induc Dis"},{"key":"R9-4-20241212","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","article-title":"How will country-based mitigation measures influence the course of the COVID-19 epidemic?","volume":"395","author":"Anderson","year":"2020","journal-title":"Lancet"},{"key":"R10-4-20241212","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","volume":"382","author":"Zou","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-4-20241212","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis","volume":"34","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"R13-4-20241212","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","article-title":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study","volume":"20","author":"Shi","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R14-4-20241212","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R18-4-20241212","doi-asserted-by":"crossref","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Eur Surveill"},{"key":"R20-4-20241212","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R21-4-20241212","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/jcm8060786","article-title":"Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients","volume":"8","author":"Voiriot","year":"2019","journal-title":"J Clin Med"},{"key":"R22-4-20241212","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"R24-4-20241212","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"R25-4-20241212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"R29-4-20241212","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"R32-4-20241212","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Jun","year":"2020","journal-title":"J Zhejiang Univ (Med Sci"},{"key":"R34-4-20241212","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: Initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"R35-4-20241212","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"R37-4-20241212","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomized, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"R38-4-20241212","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","volume":"34","author":"Al-Tawfiq","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"R41-4-20241212","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"R43-4-20241212","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"R44-4-20241212","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"R45-4-20241212","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R46-4-20241212","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee","year":"2004","journal-title":"J Clin Virol"},{"key":"R47-4-20241212","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R48-4-20241212","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10096-005-0004-z","article-title":"Treatment of severe acute respiratory syndrome","volume":"24","author":"Lai","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R49-4-20241212","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"key":"R50-4-20241212","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"R51-4-20241212","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"R52-4-20241212","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"R53-4-20241212","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R54-4-20241212","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","volume":"46","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med"},{"key":"R55-4-20241212","doi-asserted-by":"crossref","first-page":"e35797","DOI":"10.1371\/journal.pone.0035797","article-title":"Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review","volume":"7","author":"Tran","year":"2012","journal-title":"PLoS One"},{"key":"R62-4-20241212","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","volume":"382","author":"van Doremalen","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.IJMR_957_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:03:11Z","timestamp":1751497391000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/clinical-management-of-covid-19\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_957_20","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}